Staphylococcus aureus and Staphylococcus lugdunensis (S. aureus and S. lugdunensis)

Staphylococcus aureus and Staphylococcus lugdunensis are Gram-positive, cocci-shaped bacteria that represent significant human pathogens. Staphylococcus aureus is a leading cause of both community-acquired and healthcare-associated infections, ranging from superficial skin abscesses to life-threatening conditions such as bacteremia, pneumonia, and toxic shock syndrome (StatPearls, 2023). It is distinguished by its production of coagulase and a wide array of virulence factors that facilitate tissue invasion and immune evasion (PubMed, 2021). Staphylococcus lugdunensis, although classified as a coagulase-negative staphylococcus, is notably more aggressive than other members of its group and is frequently associated with virulent endocarditis and skin infections (NIH, 2020). Both species are treated with various classes of antibiotics, but the emergence of methicillin-resistant S. aureus (MRSA) has necessitated the use of last-resort agents like vancomycin and daptomycin (CDC, 2019). These organisms are not single molecular targets but are complex pathogens containing numerous potential therapeutic targets, such as penicillin-binding proteins and ribosomal subunits (UniProt, 2023). Understanding the distinct pathogenic profiles of these two species is crucial for effective diagnosis and treatment in clinical settings.

Other names

S. aureusS. lugdunensisStaph aureusStaph lugdunensisGolden StaphCoagulase-positive staphylococciCoagulase-negative staphylococci

Antibiotics targeting these organisms primarily function by inhibiting cell wall peptidoglycan synthesis, disrupting protein synthesis at the ribosomal level, or interfering with DNA gyrase and topoisomerase activity.